Quality of life in patients (pts) with Relapsed and Refractory Multiple Myeloma (RRMM) treated with the BCMA-DIRECTED CAR T cell therapy Idecabtagene Vicleucel (IDE-CEL, bb2121): Results from the KarMMa trial

被引：0
|
作者：
Weisel, K. [1 ]
Einsele, H. [2 ]
Goldschmidt, H. [3 ,4 ]
Delforge, M. [5 ]
San Miguel, J. [6 ]
Bertin, K. B. [7 ]
Tahir, M. [7 ]
Lewis, H. [8 ]
Wang, J. [9 ]
Braverman, J. [9 ]
Campbell, T. B. [9 ]
Munshi, N. [10 ,11 ,12 ]
机构：
[1] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany
[2] Univ Hosp Wurzburg, Wurzburg, Germany
[3] Univ Hosp Heidelberg, Internal Med 5, Heidelberg, Germany
[4] Univ Hosp Heidelberg, Natl Ctr Tumor Dis NCT, Heidelberg, Germany
[5] Univ Hosp Leuven, Leuven, Belgium
[6] Univ Navarra Clin, Pamplona, Spain
[7] ICON Plc, San Francisco, CA USA
[8] ICON Plc, London, England
[9] Bristol Myers Squibb, Princeton, NJ USA
[10] Harvard Med Sch, Boston, MA 02115 USA
[11] Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA
[12] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2020年 / 43卷 / SUPPL 4期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
214
引用
收藏
页码：93 / 94
页数：2
相关论文
共 50 条
  • [31] Idecabtagene Vicleucel (ide-cel, bb2121) in Relapsed and Refractory Multiple Myeloma: Analyses of High-Risk Subgroups in the KarMMa Study
    Raje, Noopur S.
    Siegel, David S.
    Jagannath, Sundar
    Lonial, Sagar
    Munshi, Nikhil C.
    Moreau, Philippe
    Goldschmidt, Hartmut
    Cavo, Michele
    Truppel-Hartmann, Anna
    Rowe, Everton
    Huang, Liping
    Agarwal, Amit
    Wang, Julie
    Campbell, Timothy B.
    San-Miguel, Jesus F.
    Reece, Donna E.
    BLOOD, 2020, 136
  • [32] Idecabtagene Vicleucel (ide-cel, bb2121) in Relapsed and Refractory Multiple Myeloma (RRMM): Analyses of high-risk patient (Pt) subgroups in the KarMMa study
    Goldschmidt, H.
    Raje, N. S.
    Siegel, D.
    Jagannath, S.
    Lonial, S.
    Munshi, N. C.
    Moreau, P.
    Cavo, M.
    Truppel-Hartmann, A.
    Rowe, E.
    Huang, L.
    Agarwal, A.
    Wang, J.
    Campbell, T. B.
    San-Miguel, J.
    Reece, D. E.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 18 - 19
  • [33] Subsequent Anti-Myeloma Therapy after Idecabtagene Vicleucel (ide-cel, bb2121) Treatment in Patients with Relapsed/Refractory Multiple Myeloma from the KarMMa Study
    Rodriguez-Otero, Paula
    San-Miguel, Jesus F.
    Anderson, Larry D., Jr.
    Lonial, Sagar
    Truppel-Hartmann, Anna
    Sanford, Jill
    Rowe, Everton
    Campbell, Timothy B.
    Munshi, Nikhil C.
    BLOOD, 2021, 138
  • [34] Characteristics of neurotoxicity associated with idecabtagene vicleucel (ide-cel, bb2121) in patients with relapsed and refractory multiple myeloma (RRMM) in the pivotal phase II KarMMa study.
    Manier, Salomon
    Kansagra, Ankit J.
    Anderson, Larry D., Jr.
    Berdeja, Jesus G.
    Jagannath, Sundar
    Lin, Yi
    Lonial, Sagar
    Shah, Nina
    Raje, Noopur S.
    Siegel, David Samuel DiCapua
    Oriol, Albert
    Truppel-Hartmann, Anna
    Rowe, Everton
    Patel, Payal
    Agarwal, Amit
    Campbell, Timothy B.
    Rodriguez-Otero, Paula
    Munshi, Nikhil C.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [35] ESTIMATION OF POST-INFUSION COSTS OF CARE FOR PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM) WHO RECEIVED IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) IN THE KARMMA CLINICAL TRIAL
    Hari, P.
    Nguyen, A.
    Pelletier, C.
    Hege, K.
    McGarvey, N.
    Gitlin, M.
    Parikh, K.
    VALUE IN HEALTH, 2021, 24 : S29 - S30
  • [36] Characteristics of neurotoxicity associated with idecabtagene vicleucel (ide-cel, bb2121) in patients with relapsed and refractory multiple myeloma in the pivotal phase 2 KarMMa study
    Weisel, K.
    Manier, S.
    Kansagra, A.
    Anderson, Jr L. D.
    Berdeja, J.
    Jagannath, S.
    Lin, Y.
    Lonial, S.
    Shah, N.
    Raje, N.
    Siegel, D.
    Oriol, A.
    Truppel-Hartmann, A.
    Rowe, E.
    Patel, P.
    Agarwal, A.
    Campbell, T. B.
    Rodriguez-Otero, P.
    Munshi, N.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 179 - 180
  • [37] Estimation of post-infusion costs of care for patients in the US with relapsed and refractory multiple myeloma (RRMM) who received idecabtagene vicleucel (ide-cel, bb2121) in the KarMMa clinical trial
    McGarvey, November
    Ung, Brian
    Carattini, Thomas
    Campbell, Timothy
    Lee, Abraham
    Patwardhan, Pallavi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S181 - S181
  • [38] KARMMA STUDY: CHARACTERIZATION OF CYTOKINE RELEASE SYNDROME (CRS) IN PATIENTS (PTS) WITH MULTIPLE RELAPSE/REFRACTORY MYELOMA (MMRR) TREATED WITH IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121)
    Albert, Oriol
    Ankit, Kansagra
    Yi, Lin
    Jesus, Berdeja
    Nina, Shah
    Ibrahim, Yakoub-Agha
    Hermann, Einsele
    Alessandro, Rambaldi
    Anna, Truppel-Hartmann
    Everton, Rowe
    Julie, Wang
    Amit, Agarwal
    Timothy, Campbell B.
    Sagar, Lonial
    HAEMATOLOGICA, 2021, 106 (10) : 77 - 78
  • [39] The BCMA CAR T cell therapy idecabtagene vicleucel (ide-cel/bb2121) in relapsed and refractory multiple myeloma (RRMM): outcomes from phase 1 study support the phase 3 KarMMa-3 study design to compare ide-cel versus standard triplet regimens
    Einsele, H.
    Raab, M.
    Kroeger, N.
    Fenk, R.
    Scheid, C.
    Munshi, N.
    Petrocca, F.
    Hege, K.
    Novick, S.
    Raje, N.
    Kochenderfer, J. N.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 140 - 141
  • [40] Correlative analysis to define patient profiles associated with manufacturing and clinical endpoints in relapsed/refractory multiple myeloma (RRMM) patients treated with idecabtagene vicleucel (ide-cel; bb2121), an anti-BCMA CAR T cell therapy.
    Rytlewski, Julie
    Fuller, Jaymes
    Mertz, David R.
    Freeman, Ciara
    Manier, Salomon
    Shah, Nina
    Campbell, Timothy Brandon
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345